Highest-materiality recent filing
Teva shareholders re-elect Sol J. Barer to board, approve advisory pay vote
Dr. Sol J. Barer elected to board with 627.8M for, 245.9M against, 0.5M abstain (broker non-votes 50.7M).
Teva Q1 revenues $4.0B (+2% YoY); AUSTEDO up 41%; to acquire Emalex for $700M cash
Q1 GAAP diluted EPS $0.31; Non-GAAP diluted EPS $0.53; revenues $3,982M (+2% USD, -3% LC).
Teva posts FY 2025 revenue $17.3B (+4% YoY), non-GAAP EPS $2.93, guides FY26 rev $16.4-16.8B
FY 2025 revenues $17.3B (+4% YoY); GAAP diluted EPS $1.21, non-GAAP diluted EPS $2.93.
Teva pre-announces 2025 revenue $16.8-$17.0B, raises guidance; projects 2030 mid-single-digit CAGR
Expected 2025 revenue $16.8-$17.0B (low end), adjusted EBITDA $4.8-$5.0B (midpoint).
Teva extends revolving credit facility maturity to April 2028, adjusts leverage covenants
Maturity extended from April 2027 to April 2028 via second one-year extension of the revolving facility.
Teva Q3 2025: revenue $4.48B (+3%), non-GAAP EPS $0.78; Austedo outlook raised; TAPI sale restart
Revenue $4.48B (+3% YoY); GAAP EPS $0.37, non-GAAP EPS $0.78 (vs $0.69 YoY).
Teva Q2 2025 Non-GAAP EPS $0.66 (+9% YoY); Raises 2025 Innovative Product Revenue Outlook
Revenues $4.176B flat YoY; GAAP EPS $0.24; Non-GAAP EPS $0.66 (up from $0.61).
Teva shareholders elect board, approve executive compensation and auditor at annual meeting
Chen Lichtenstein elected to board until 2027; Amir Elstein, Roberto Mignone, Perry Nisen, Tal Zaks elected until 2028.
Teva issues €1B and $1.2B in senior notes to refinance debt, upsizes tender offer to $2.25B
€1B of 4.125% Senior Notes due 2031; $500M of 6.000% notes due 2032; $700M of 5.750% notes due 2030.
Teva prices $2.3B multi-tranche senior notes offering to refinance existing debt
Upsized offering from $2B to ~$2.3B equivalent across three tranches.
Teva Q1 2025: revenue $3.9B (+5% LC), Non-GAAP EPS $0.52 (+8% YoY); raises FY outlook
Q1 revenue $3.9B (+5% local currency, +2% reported); GAAP EPS $0.18, Non-GAAP EPS $0.52 (vs $0.48 YoY).
Teva FY2024 revenue $16.5B, GAAP EPS loss $1.45; non-GAAP EPS $2.49; sees 2025 rev $16.8-17.4B
FY2024 revenues $16.5B, +4% USD (+6% local currency); GAAP net loss $1.639B ($1.45/share) vs $559M loss in FY2023.
Teva elects Chen Lichtenstein to board effective Dec 1, 2024
Chen Lichtenstein elected as independent director, effective Dec 1, 2024, until 2025 annual meeting.
Teva Q3 rev $4.3B (+13% YoY); raises FY2024 guidance; Austedo $435M (+28%)
Q3 revenues $4.3B (+13% USD, +15% local currency); Non-GAAP diluted EPS $0.69 vs $0.60 YoY.
Teva Q2 revenue $4.2B +7%, non-GAAP EPS $0.61, raises full-year 2024 guidance
Revenue $4.2B (+7% USD, +11% local currency); GAAP loss $0.75/share, non-GAAP EPS $0.61.
Teva settles Israeli tax dispute for ~$750M over 2008-2020, plus up to $500M contingent
Teva to pay ~$750M to Israeli Tax Authorities over 2024-2029 for tax years 2008-2020.
Teva shareholders elect four directors, approve say-on-pay and auditor at annual meeting
Elected Prof. Varda Shalev to board through 2026; Rosemary Crane, Gerald Lieberman, Prof. Ronit Satchi-Fainaro through 2027.
Teva appoints Matthew Shields as EVP Global Operations; Eric Drapé departs after 11 years
Matthew Shields becomes EVP Global Operations effective June 3, 2024, based in Parsippany, NJ.
Teva Q1 revenue $3.8B (+4% YoY), non-GAAP EPS $0.48, reaffirms FY24 guidance
Revenue $3.819B (+4% YoY, +5% local currency); generics up 9% globally.
the Board elected Mr. Chen Lichtenstein to serve as a member of the Board, effective December 1, 2024
Mr. Eric Drapé, Executive Vice President, Global Operations, will be leaving Teva Pharmaceutical Industries Ltd.
Mr. Matthew Shields has been appointed as Executive Vice President, Global Operations of Teva and a member of Teva Executive Management, effective June 3, 2024.
Max materiality 0.85 · Median 0.75 · Most common event earnings